Europe Neutropenia Treatment Market By Distribution channel (Retail pharmacies, Hospital pharmacies and Online pharmacies), By Treatment (Colony-stimulating factor, Antibiotics, Antifungals and Antivirals), By Country, Industry Analysis and Forecast, 2020 - 2026
The Europe Neutropenia Treatment Market would witness market growth of 6.2% CAGR during the forecast period (2020-2026).
Neutropenia occurs when a person has low levels of neutrophils, a type of white blood cell. Neutrophils are formed in the bone marrow, which is the spongy tissue contained in larger bones, such as the vertebrae, ribs, and pelvis. White blood cells help the body battle infections. Neutrophils fight infection by removing toxic fungi, yeast, and bacteria that invade the body. People with neutropenia are at greater risk of contracting severe infections. Half of the cancer patients undergoing chemotherapy experience a level of neutropenia. Neutropenia is a common side effect in people with leukemia.
Growing cases of leukemia across the globe and a shift to the use of biosimilars from branded drugs in cancer-supporting treatment are driving the growth of the global neutropenia treatment market. Nevertheless, the high cost of treatment associated with neutropenia and the strict government regulations for product approval reduce the growth of the market. On the other hand, the increase in R&D activities for the development of new drugs creates new opportunities for market players in the coming years.
Novel treatments combined with growing cases of chemotherapy-induced neutropenia are one of the primary drivers of market growth. In addition, the novel drug delivery strategy also increases patient convenience, leading to greater adherence to the patient and thereby stimulates the growth of the market. Moreover, since cancer is a known cause of developing neutropenia, increasing cases of chemotherapy for cancer treatment will be a growth driver for the neutropenia treatment market.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
Neutropenia occurs when a person has low levels of neutrophils, a type of white blood cell. Neutrophils are formed in the bone marrow, which is the spongy tissue contained in larger bones, such as the vertebrae, ribs, and pelvis. White blood cells help the body battle infections. Neutrophils fight infection by removing toxic fungi, yeast, and bacteria that invade the body. People with neutropenia are at greater risk of contracting severe infections. Half of the cancer patients undergoing chemotherapy experience a level of neutropenia. Neutropenia is a common side effect in people with leukemia.
Growing cases of leukemia across the globe and a shift to the use of biosimilars from branded drugs in cancer-supporting treatment are driving the growth of the global neutropenia treatment market. Nevertheless, the high cost of treatment associated with neutropenia and the strict government regulations for product approval reduce the growth of the market. On the other hand, the increase in R&D activities for the development of new drugs creates new opportunities for market players in the coming years.
Novel treatments combined with growing cases of chemotherapy-induced neutropenia are one of the primary drivers of market growth. In addition, the novel drug delivery strategy also increases patient convenience, leading to greater adherence to the patient and thereby stimulates the growth of the market. Moreover, since cancer is a known cause of developing neutropenia, increasing cases of chemotherapy for cancer treatment will be a growth driver for the neutropenia treatment market.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies and
- Online pharmacies
- Colony-stimulating factor
- Antibiotics
- Antifungals and
- Antivirals
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Amgen, Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- BeyondSpring, Inc.
- Spectrum Pharmaceuticals, Inc.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Mylan N.V.
- Cellerant Therapeutics, Inc.
- Partner Therapeutics, Inc.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Neutropenia Treatment Market, by Distribution Channel
1.4.2 Europe Neutropenia Treatment Market, by Treatment
1.4.3 Europe Neutropenia Treatment Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL
3.1 Europe Retail pharmacies Market by Country
3.2 Europe Hospital pharmacies Market by Country
3.3 Europe Online pharmacies Market by Country
CHAPTER 4. EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT
4.1 Europe Colony-stimulating factor Market by Country
4.2 Europe Antibiotics Market by Country
4.3 Europe Antifungals Market by Country
4.4 Europe Antivirals Market by Country
CHAPTER 5. EUROPE NEUTROPENIA TREATMENT MARKET BY COUNTRY
5.1 Germany Neutropenia Treatment Market
5.1.1 Germany Neutropenia Treatment Market by Distribution channel
5.1.2 Germany Neutropenia Treatment Market by Treatment
5.2 UK Neutropenia Treatment Market
5.2.1 UK Neutropenia Treatment Market by Distribution channel
5.2.2 UK Neutropenia Treatment Market by Treatment
5.3 France Neutropenia Treatment Market
5.3.1 France Neutropenia Treatment Market by Distribution channel
5.3.2 France Neutropenia Treatment Market by Treatment
5.4 Russia Neutropenia Treatment Market
5.4.1 Russia Neutropenia Treatment Market by Distribution channel
5.4.2 Russia Neutropenia Treatment Market by Treatment
5.5 Spain Neutropenia Treatment Market
5.5.1 Spain Neutropenia Treatment Market by Distribution channel
5.5.2 Spain Neutropenia Treatment Market by Treatment
5.6 Italy Neutropenia Treatment Market
5.6.1 Italy Neutropenia Treatment Market by Distribution channel
5.6.2 Italy Neutropenia Treatment Market by Treatment
5.7 Rest of Europe Neutropenia Treatment Market
5.7.1 Rest of Europe Neutropenia Treatment Market by Distribution channel
5.7.2 Rest of Europe Neutropenia Treatment Market by Treatment
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Neutropenia Treatment Market, by Distribution Channel
1.4.2 Europe Neutropenia Treatment Market, by Treatment
1.4.3 Europe Neutropenia Treatment Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL
3.1 Europe Retail pharmacies Market by Country
3.2 Europe Hospital pharmacies Market by Country
3.3 Europe Online pharmacies Market by Country
CHAPTER 4. EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT
4.1 Europe Colony-stimulating factor Market by Country
4.2 Europe Antibiotics Market by Country
4.3 Europe Antifungals Market by Country
4.4 Europe Antivirals Market by Country
CHAPTER 5. EUROPE NEUTROPENIA TREATMENT MARKET BY COUNTRY
5.1 Germany Neutropenia Treatment Market
5.1.1 Germany Neutropenia Treatment Market by Distribution channel
5.1.2 Germany Neutropenia Treatment Market by Treatment
5.2 UK Neutropenia Treatment Market
5.2.1 UK Neutropenia Treatment Market by Distribution channel
5.2.2 UK Neutropenia Treatment Market by Treatment
5.3 France Neutropenia Treatment Market
5.3.1 France Neutropenia Treatment Market by Distribution channel
5.3.2 France Neutropenia Treatment Market by Treatment
5.4 Russia Neutropenia Treatment Market
5.4.1 Russia Neutropenia Treatment Market by Distribution channel
5.4.2 Russia Neutropenia Treatment Market by Treatment
5.5 Spain Neutropenia Treatment Market
5.5.1 Spain Neutropenia Treatment Market by Distribution channel
5.5.2 Spain Neutropenia Treatment Market by Treatment
5.6 Italy Neutropenia Treatment Market
5.6.1 Italy Neutropenia Treatment Market by Distribution channel
5.6.2 Italy Neutropenia Treatment Market by Treatment
5.7 Rest of Europe Neutropenia Treatment Market
5.7.1 Rest of Europe Neutropenia Treatment Market by Distribution channel
5.7.2 Rest of Europe Neutropenia Treatment Market by Treatment
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:
LIST OF TABLES
TABLE 1 EUROPE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 2 EUROPE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 3 EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 4 EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 5 EUROPE RETAIL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 EUROPE RETAIL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 EUROPE HOSPITAL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 EUROPE HOSPITAL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 EUROPE ONLINE PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 EUROPE ONLINE PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 12 EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 13 EUROPE COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 EUROPE COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 EUROPE ANTIBIOTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 EUROPE ANTIBIOTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 EUROPE ANTIFUNGALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 EUROPE ANTIFUNGALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 EUROPE ANTIVIRALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 EUROPE ANTIVIRALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 EUROPE NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 EUROPE NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 GERMANY NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 24 GERMANY NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 25 GERMANY NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 26 GERMANY NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 27 GERMANY NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 28 GERMANY NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 29 UK NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 30 UK NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 31 UK NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 32 UK NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 33 UK NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 34 UK NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 35 FRANCE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 36 FRANCE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 37 FRANCE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 38 FRANCE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 39 FRANCE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 – 2019, USD MILLION
TABLE 40 FRANCE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 41 RUSSIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 42 RUSSIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 43 RUSSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 44 RUSSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 45 RUSSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 46 RUSSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 47 SPAIN NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 48 SPAIN NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 49 SPAIN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 50 SPAIN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 51 SPAIN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 52 SPAIN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 53 ITALY NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 54 ITALY NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 55 ITALY NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 56 ITALY NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 57 ITALY NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 58 ITALY NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 59 REST OF EUROPE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 60 REST OF EUROPE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 61 REST OF EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 62 REST OF EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 63 REST OF EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 64 REST OF EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 65 KEY INFORMATION – AMGEN, INC.
TABLE 66 KEY INFORMATION – NOVARTIS AG
TABLE 67 KEY INFORMATION – PFIZER, INC.
TABLE 68 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 69 KEY INFORMATION – BEYONDSPRING, INC.
TABLE 70 KEY INFORMATION – SPECTRUM PHARMACEUTICALS, INC.
TABLE 71 KEY INFORMATION – KYOWA KIRIN CO., LTD.
TABLE 72 KEY INFORMATION – MYLAN N.V.
TABLE 73 KEY INFORMATION – CELLERANT THERAPEUTICS, INC.
TABLE 74 KEY INFORMATION – PARTNER THERAPEUTICS, INC.
TABLE 1 EUROPE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 2 EUROPE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 3 EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 4 EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 5 EUROPE RETAIL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 EUROPE RETAIL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 EUROPE HOSPITAL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 EUROPE HOSPITAL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 EUROPE ONLINE PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 EUROPE ONLINE PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 12 EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 13 EUROPE COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 EUROPE COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 EUROPE ANTIBIOTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 EUROPE ANTIBIOTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 EUROPE ANTIFUNGALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 EUROPE ANTIFUNGALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 EUROPE ANTIVIRALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 EUROPE ANTIVIRALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 EUROPE NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 EUROPE NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 GERMANY NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 24 GERMANY NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 25 GERMANY NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 26 GERMANY NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 27 GERMANY NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 28 GERMANY NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 29 UK NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 30 UK NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 31 UK NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 32 UK NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 33 UK NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 34 UK NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 35 FRANCE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 36 FRANCE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 37 FRANCE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 38 FRANCE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 39 FRANCE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 – 2019, USD MILLION
TABLE 40 FRANCE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 41 RUSSIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 42 RUSSIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 43 RUSSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 44 RUSSIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 45 RUSSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 46 RUSSIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 47 SPAIN NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 48 SPAIN NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 49 SPAIN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 50 SPAIN NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 51 SPAIN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 52 SPAIN NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 53 ITALY NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 54 ITALY NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 55 ITALY NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 56 ITALY NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 57 ITALY NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 58 ITALY NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 59 REST OF EUROPE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 60 REST OF EUROPE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 61 REST OF EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 62 REST OF EUROPE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 63 REST OF EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 64 REST OF EUROPE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 65 KEY INFORMATION – AMGEN, INC.
TABLE 66 KEY INFORMATION – NOVARTIS AG
TABLE 67 KEY INFORMATION – PFIZER, INC.
TABLE 68 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 69 KEY INFORMATION – BEYONDSPRING, INC.
TABLE 70 KEY INFORMATION – SPECTRUM PHARMACEUTICALS, INC.
TABLE 71 KEY INFORMATION – KYOWA KIRIN CO., LTD.
TABLE 72 KEY INFORMATION – MYLAN N.V.
TABLE 73 KEY INFORMATION – CELLERANT THERAPEUTICS, INC.
TABLE 74 KEY INFORMATION – PARTNER THERAPEUTICS, INC.
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
